Status:
COMPLETED
Study of Intravenous and Subcutaneous Administration of Risankizumab in Healthy Participants
Lead Sponsor:
AbbVie
Conditions:
Healthy Volunteers
Eligibility:
All Genders
18-60 years
Phase:
PHASE1
Brief Summary
The primary objectives of this study are to assess the relative bioavailability of risankizumab in on-body delivery system (OBDS) versus the prefilled syringe (PFS) (Substudy 1) and to assess the rela...
Eligibility Criteria
Inclusion
- \- Body weight less than 100.00 kg at Screening and upon initial confinement.
Exclusion
- \- Previous exposure to any anti-IL-12/23 or anti-IL-23 treatment.
Key Trial Info
Start Date :
September 1 2020
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
July 6 2021
Estimated Enrollment :
394 Patients enrolled
Trial Details
Trial ID
NCT05274100
Start Date
September 1 2020
End Date
July 6 2021
Last Update
March 10 2022
Active Locations (8)
Enter a location and click search to find clinical trials sorted by distance.
1
Anaheim Clinical Trials LLC /ID# 222821
Anaheim, California, United States, 92801-2658
2
Altasciences Clinical Los Angeles, Inc /ID# 222238
Cypress, California, United States, 90630
3
Clinical Pharmacology of Miami /ID# 225392
Miami, Florida, United States, 33014
4
PPD Clinical Research Unit /ID# 222362
Orlando, Florida, United States, 32806-1044